CNN-Based AI Model Targets Dermoscopic Risk Stratification of Basal Cell Carcinoma Subtypes — Trial of 2,500 Cases Opens in Istanbul

References

1. 1.Istanbul Training and Research Hospital. (2025). Risk classification and prediction of histopathological subtypes in basal cell carcinoma using a CNN-based artificial intelligence model on dermoscopic images (NCT07677124). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07677124
2. 2.Peris, K., Fargnoli, M. C., Garbe, C., Kaufmann, R., Bastholt, L., Seguin, N. B., Bataille, V., Marmol, V. D., Dummer, R., Harwood, C. A., Hauschild, A., Höller, C., Haedersdal, M., Malvehy, J., Middleton, M. R., Morton, C. A., Nagore, E., Stratigos, A. J., Szeimies, R. M., … Eggermont, A. M. M. (2019). Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. European Journal of Cancer, 118, 10–34. https://doi.org/10.1016/j.ejca.2019.06.003
3. 3.Crowson, A. N. (2006). Basal cell carcinoma: biology, morphology and clinical implications. Modern Pathology, 19(Suppl 2), S127–S147. https://doi.org/10.1038/modpathol.3800512
4. 4.Combalia, A., & Carrera, C. (2020). Dermoscopy of basal cell carcinoma: a systematic review of its diagnostic accuracy. Actas Dermo-Sifiliográficas, 111(8), 671–678. https://doi.org/10.1016/j.ad.2019.11.009
5. 5.Therapeutic Goods Administration. (2023). Software as a medical device (SaMD): Guidance for industry. Australian Government Department of Health and Aged Care. https://www.tga.gov.au/resources/publication/guidance/software-medical-device-samd
6. 6.Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118. https://doi.org/10.1038/nature21056